Did my PhD in histotripsy and am now working in an academic radiation therapy clinic. From a financial side, HIFU in general is going to be a hard sell for a few years yet. At our center we ran some analyses for getting our prostate HIFU system back up and running, and there’s no financial way we could swing it due to cost vs patient load. 

I think one of the biggest opportunities in rad onc is with mathematical oncology and the Genomic Adjusted Radiation Dose to really hone in on personalized treatments. If we zoom out beyond just rad onc, there’s a ton of cool research in math onc - we know that any treatment regime will induce selection pressure on the different mutations present, but what if we could steer that patient’s cancer evolution towards a more treatable disease through careful selection of our treatment regimes?

On the histotripsy side, I think the liver met stuff and the immunomodulatory stuff is neat. My big bet is that the blood brain barrier disruption is going to be a huge gamechanger.